Novartis sharpens focus on vision-restoring gene therapy with $150M Vedere buyout

Vedere Bio didn’t stand a chance.

The Atlas Venture gene therapy startup was working under the radar and contemplating another venture round when it got an offer it couldn’t refuse: $150 million upfront to become part of Novartis, with another $130 million promised if it hits certain goals.